Topline results from the phase III MVOR-1 and MVOR-2 trials comparing DFD 29 against Galderma’s Oracea in papulopustular rosacea
Journey Medical Corporation announced positive topline results from the two Phase III multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea in Rosacea-1 (“MVOR-1”) and Minocycline Versus Oracea in Rosacea-2 (“MVOR-2”), evaluating Minocycline Hydrochloride Modified Release Capsules, 40 mg (“DFD 29”) for the treatment of moderate-to-severe papulopustular rosacea in adults